OABI vs. ABSI, MXCT, KALV, CABA, APLT, VERV, ZJYL, ATXS, CYH, and YMAB
Should you be buying OmniAb stock or one of its competitors? The main competitors of OmniAb include Absci (ABSI), MaxCyte (MXCT), KalVista Pharmaceuticals (KALV), Cabaletta Bio (CABA), Applied Therapeutics (APLT), Verve Therapeutics (VERV), Jin Medical International (ZJYL), Astria Therapeutics (ATXS), Community Health Systems (CYH), and Y-mAbs Therapeutics (YMAB). These companies are all part of the "medical" sector.
Absci (NASDAQ:ABSI) and OmniAb (NASDAQ:OABI) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, community ranking, analyst recommendations, valuation, risk, dividends, media sentiment and institutional ownership.
Absci received 4 more outperform votes than OmniAb when rated by MarketBeat users. However, 100.00% of users gave OmniAb an outperform vote while only 53.66% of users gave Absci an outperform vote.
OmniAb has a net margin of -301.62% compared to OmniAb's net margin of -2,042.01%. Absci's return on equity of -19.93% beat OmniAb's return on equity.
Absci has a beta of 2.39, meaning that its stock price is 139% more volatile than the S&P 500. Comparatively, OmniAb has a beta of -0.08, meaning that its stock price is 108% less volatile than the S&P 500.
In the previous week, Absci and Absci both had 15 articles in the media. OmniAb's average media sentiment score of 0.13 beat Absci's score of 0.06 indicating that Absci is being referred to more favorably in the media.
52.1% of Absci shares are held by institutional investors. Comparatively, 72.1% of OmniAb shares are held by institutional investors. 9.8% of Absci shares are held by insiders. Comparatively, 7.0% of OmniAb shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Absci currently has a consensus target price of $9.25, indicating a potential upside of 100.43%. OmniAb has a consensus target price of $9.00, indicating a potential upside of 102.25%. Given Absci's higher probable upside, analysts plainly believe OmniAb is more favorable than Absci.
OmniAb has higher revenue and earnings than Absci. OmniAb is trading at a lower price-to-earnings ratio than Absci, indicating that it is currently the more affordable of the two stocks.
Summary
OmniAb beats Absci on 9 of the 15 factors compared between the two stocks.
Get OmniAb News Delivered to You Automatically
Sign up to receive the latest news and ratings for OABI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OABI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
